Common TDP1 Polymorphisms in Relation to Survival among Small Cell Lung Cancer Patients: A Multicenter Study from the International Lung Cancer Consortium
Open Access
- 14 December 2017
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 23 (24) , 7550-7557
Abstract
Purpose: DNA topoisomerase inhibitors are commonly used for treating small-cell lung cancer (SCLC). Tyrosyl-DNA phosphodiesterase (TDP1) repairs DNA damage caused by this class of drugs and may therefore influence treatment outcome. In this study, we investigated whether common TDP1 single-nucleotide polymorphisms (SNP) are associated with overall survival among SCLC patients. Experimental Design: Two TDP1 SNPs (rs942190 and rs2401863) were analyzed in 890 patients from 10 studies in the International Lung Cancer Consortium (ILCCO). The Kaplan–Meier method and Cox regression analyses were used to evaluate genotype associations with overall mortality at 36 months postdiagnosis, adjusting for age, sex, race, and tumor stage. Results: Patients homozygous for the minor allele (GG) of rs942190 had poorer survival compared with those carrying AA alleles, with a HR of 1.36 [95% confidence interval (CI): 1.08–1.72, P = 0.01), but no association with survival was observed for patients carrying the AG genotype (HR = 1.04, 95% CI, 0.84–1.29, P = 0.72). For rs2401863, patients homozygous for the minor allele (CC) tended to have better survival than patients carrying AA alleles (HR = 0.79; 95% CI, 0.61–1.02, P = 0.07). Results from the Genotype Tissue Expression (GTEx) Project, the Encyclopedia of DNA Elements (ENCODE), and the ePOSSUM web application support the potential function of rs942190. Conclusions: We found the rs942190 GG genotype to be associated with relatively poor survival among SCLC patients. Further investigation is needed to confirm the result and to determine whether this genotype may be a predictive marker for treatment efficacy of DNA topoisomerase inhibitors. Clin Cancer Res; 23(24); 7550–7. ©2017 AACR.Keywords
All Related Versions
Funding Information
- NIH (U19 CA148127)
- NIH (R03-CA77118, R01s-CA80127, CA84354, HL107612)
- NIH (5-UM1-CA-167462, U01-CA63673, R01-CA111703)
- NIH (R01CA092824, R01CA074386, P30 ES000002)
- U.S. Department of War (10153006, (W81XWH-11-1-0781))
- NIH (UL1TR000117)
- NCI (P30 CA177558)
- Canadian Cancer Society Research Institute (020214)
- James & Esther King Biomedical Research (09KN-15)
- NIH (P50 CA119997)
- American Cancer Society (93-032-13)
This publication has 43 references indexed in Scilit:
- An integrated encyclopedia of DNA elements in the human genomeNature, 2012
- Tyrosyl-DNA Phosphodiesterase 1 (TDP1) Repairs DNA Damage Induced by Topoisomerases I and II and Base Alkylation in Vertebrate CellsJournal of Biological Chemistry, 2012
- A User's Guide to the Encyclopedia of DNA Elements (ENCODE)PLOS Biology, 2011
- Interference with Activator Protein-2 transcription factors leads to induction of apoptosis and an increase in chemo- and radiation-sensitivity in breast cancer cellsBMC Cancer, 2010
- Pharmacodynamic Genes do not Influence Risk of Neutropenia in Cancer Patients Treated with Moderately High-Dose IrinotecanPharmacogenomics, 2009
- SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studiesNucleic Acids Research, 2009
- Increased expression and activity of repair genes TDP1 and XPF in non-small cell lung cancerLung Cancer, 2007
- Tyrosyl-DNA phosphodiesterase (Tdp1) participates in the repair of Top2-mediated DNA damageProceedings of the National Academy of Sciences, 2006
- Estimating haplotype frequencies and standard errors for multiple single nucleotide polymorphismsBiostatistics, 2003
- Myc—Max—Mad: a transcription factor network controlling cell cycle progression, differentiation and deathCurrent Opinion in Genetics & Development, 1994